NeOnc Technologies announced preclinical findings demonstrating ultrasound's enhancement of NEO100's potency in treating primary and metastatic brain tumors.
The study, published by researchers at USC, highlights NEO100's effectiveness when combined with focused ultrasound parameters, showing strong antitumor effects.
Utilizing AI-driven technology and 3D-bioprinted tumor organoids, the research validates NEO100 as a leading sonosensitizer with potential for clinical trials.
Innovative Research Collaboration
Research collaboration at the University of Southern California led to the discovery of ultrasound's enhancement of NEO100's therapeutic potency.
AI-Driven Technology
Utilizing AI-driven positive-unlabeled neural networks, NEO100 was consistently identified as a potent sonosensitizer for brain tumor treatment.
Accelerated Biomedical Research
The NAM platform, based on rapid 3D bioprinting technology, accelerates research timelines and aligns with NIH objectives to reduce animal testing.
- The integration of AI, 3D bioprinting, and ultrasound expands NEO100's commercial and clinical potential for treating a wide range of brain tumors.
- NEO100 combined with focused ultrasound shows promise as a noninvasive sonodynamic therapeutic, opening new opportunities beyond current indications.
The findings validate NEO100's potential as a revolutionary treatment for primary and metastatic brain tumors, offering hope for improved clinical outcomes and expanded therapeutic applications.